+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Next Generation Antibody Therapeutics Market - Global Forecast 2025-2030- Product Image
Next Generation Antibody Therapeutics Market - Global Forecast 2025-2030- Product Image
Sale

Next Generation Antibody Therapeutics Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 196 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6131472
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Next generation antibody therapeutics are reshaping the landscape of precision medicine, providing targeted interventions for complex diseases and transforming biopharmaceutical approaches globally. Senior decision-makers seeking a clear market overview will find actionable strategic direction in this analysis of antibody discovery, design, and commercialization.

Market Snapshot: Next Generation Antibody Therapeutics

The next generation antibody therapeutics market is defined by rapid technological innovation, a diverse range of therapeutic classes and formats, and evolving strategies to overcome global supply chain challenges. The sector benefits from intensified investment across the Americas, Europe, Middle East and Africa, and Asia-Pacific. With advancements in modular platforms, bispecific constructs, and novel conjugation techniques, companies are unlocking efficiency gains and therapeutic differentiation. Shifts in regulatory policy and payer models—along with ongoing tariff considerations in leading markets—continue to impact commercial timelines and stakeholder strategies.

Scope & Segmentation

This report delivers a robust framework for strategic planning and investment, addressing the entire value chain from R&D through to commercialization.

  • Antibody Classes and Formats: Coverage includes antibody drug conjugates (with cleavable and non-cleavable linkers), antibody fragments, bispecific antibodies (such as T cell engagers, DART, and dual variable domains), monoclonal antibodies, and radiolabeled constructs utilizing isotopes like iodine-131 and yttrium-90.
  • Therapeutic Indications: Analysis spans autoimmune disorders (including inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis, psoriasis), cardiovascular diseases (atherosclerosis, heart failure), infectious diseases (bacterial, fungal, viral), neurological disorders (Alzheimer's, Parkinson's), and oncology (hematological and solid tumors).
  • Technology Platforms: The report examines platforms such as hybridoma, phage display (immune, naïve, synthetic libraries), ribosome display, single B cell technologies (flow cytometry, microengraving), and transgenic animal models (HuMab Mouse, XenoMouse).
  • Expression Systems: Included are mammalian cell lines (CHO, NS0, SP2/0), microbial systems (Escherichia coli), plant systems (Nicotiana benthamiana), and yeast systems (Pichia pastoris, Saccharomyces cerevisiae).
  • Development Stages: Tracks the evolution from discovery and preclinical evaluation through clinical trials (Phase I–III) and commercial launch.
  • Routes of Administration: Analyzes intramuscular, intravenous, and subcutaneous delivery methods.
  • Regional Breakdown: Segments cover the Americas (including the United States—California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio—along with Canada, Mexico, Brazil, and Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, UAE, Saudi Arabia, South Africa, and others), and Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Key Companies Analyzed: The study investigates recent developments and strategies among AbbVie Inc., Roche Holding AG, Merck & Co., Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Amgen Inc., Novartis AG, Sanofi S.A., Pfizer Inc., and AstraZeneca PLC.

Key Takeaways for Senior Decision-Makers

  • Technological breakthroughs in genetic engineering, bioprocessing, and digital analytics are driving portfolio innovation and enabling more precise patient targeting.
  • Strategic collaborations—both between biopharmaceutical incumbents and biotech specialists, and cross-sectoral partnerships—are accelerating the conversion of R&D assets into commercial candidates.
  • Emerging regulatory frameworks are streamlining approval processes for complex biologics and encouraging novel outcome-based reimbursement models, reshaping the path to market.
  • Manufacturing scalability and supply chain resilience are becoming pivotal as companies navigate tariff impacts and raw material disruptions by diversifying suppliers and adopting nearshoring strategies.
  • Real-world evidence and advanced modeling tools are enabling dynamic risk assessment in pipeline investments, supporting faster decision-making and competitive differentiation.
  • Regional dynamics—such as robust contract manufacturing in the Americas, harmonized regulation in EMEA, and expanding public-private R&D ecosystems in Asia-Pacific—drive localized strategy adaptation and market prioritization.

Tariff Impact: Navigating U.S. Duties in 2025

Imposed U.S. tariffs have caused suppliers of critical materials, including linkers and radionuclides, to adapt procurement and cost frameworks. Manufacturers are evaluating alternative sources and nearshoring options to mitigate increased duties, while downstream partners renegotiate contracts to distribute the added expense. These tactical shifts require stronger cross-functional processes and inventory management, with an emphasis on transparency and supply chain fortification.

Methodology & Data Sources

This analysis employs a combination of comprehensive secondary research—including scientific literature, regulatory filings, and market reports—and primary insights through interviews with industry executives, scientists, and supply chain experts. Data triangulation confirms findings, ensuring an accurate, evidence-based perspective for leadership decisions.

Why This Report Matters

  • Provides a cohesive framework to align internal R&D, operational, and commercial objectives with shifts in technology, policy, and global markets.
  • Equips senior leaders with segmented insights for targeted investment and portfolio optimization at both macro and micro levels.
  • Delivers practical recommendations to enhance supply chain resilience, manage regulatory complexity, and capitalize on emergent therapeutic opportunities.

Conclusion

This report offers senior decision-makers a clear roadmap to anticipate industry shifts, balance innovation with operational agility, and position for sustainable growth as the next generation antibody therapeutics market advances.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of bispecific antibody formats targeting dual tumor antigens to enhance specificity and efficacy
5.2. Adoption of antibody drug conjugates with novel cytotoxic payloads for improved targeted cancer therapy
5.3. Integration of Fc engineering techniques to modulate antibody half life and effector functions in immunotherapy
5.4. Development of immune cell engagers leveraging multispecific antibodies to recruit endogenous T cells against tumors
5.5. Emergence of antibody therapeutics optimized for blood brain barrier penetration in neurodegenerative disease treatment
5.6. Growing focus on bispecific T cell engagers combined with checkpoint inhibitors to overcome tumor immune evasion
5.7. Application of AI driven antibody discovery platforms to accelerate lead identification and optimize binding affinity
5.8. Advances in next generation CAR T constructs incorporating antibody domains for precise tumor targeting
5.9. Expansion of allogeneic off the shelf antibody based cell therapies to reduce manufacturing timelines and costs
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Next Generation Antibody Therapeutics Market, by Antibody Class
8.1. Introduction
8.2. Antibody Drug Conjugates
8.2.1. Cleavable Linkers
8.2.2. Non Cleavable Linkers
8.3. Antibody Fragments
8.4. Bispecific Antibodies
8.4.1. Bispecific T Cell Engagers
8.4.2. Dart
8.4.3. Dual Variable Domain
8.5. Monoclonal Antibodies
8.6. Radiolabeled Antibodies
8.6.1. Iodine 131
8.6.2. Yttrium 90
9. Next Generation Antibody Therapeutics Market, by Target Indication
9.1. Introduction
9.2. Autoimmune Disorders
9.2.1. Inflammatory Bowel Disease
9.2.2. Multiple Sclerosis
9.2.3. Psoriasis
9.2.4. Rheumatoid Arthritis
9.3. Cardiovascular Diseases
9.3.1. Atherosclerosis
9.3.2. Heart Failure
9.4. Infectious Diseases
9.4.1. Bacterial Infections
9.4.2. Fungal Infections
9.4.3. Viral Infections
9.5. Neurological Disorders
9.5.1. Alzheimers
9.5.2. Parkinsons
9.6. Oncology
9.6.1. Hematological Malignancies
9.6.2. Solid Tumors
10. Next Generation Antibody Therapeutics Market, by Technology Platform
10.1. Introduction
10.2. Hybridoma
10.3. Phage Display
10.3.1. Immune Library
10.3.2. Naive Library
10.3.3. Synthetic Library
10.4. Ribosome Display
10.5. Single B Cell Technologies
10.5.1. Flow Cytometry
10.5.2. Microengraving
10.6. Transgenic Animals
10.6.1. HuMab Mouse
10.6.2. XenoMouse
11. Next Generation Antibody Therapeutics Market, by Expression System
11.1. Introduction
11.2. Mammalian Cells
11.2.1. CHO Cells
11.2.2. NS0 Cells
11.2.3. SP2/0 Cells
11.3. Microbial Systems
11.3.1. Escherichia Coli
11.4. Plant Systems
11.4.1. Nicotiana Benthamiana
11.5. Yeast Systems
11.5.1. Pichia Pastoris
11.5.2. Saccharomyces Cerevisiae
12. Next Generation Antibody Therapeutics Market, by Development Stage
12.1. Introduction
12.2. Clinical Trials
12.2.1. Phase I
12.2.2. Phase II
12.2.3. Phase III
12.3. Commercial
12.4. Preclinical
12.4.1. Discovery
12.4.2. Non Clinical
13. Next Generation Antibody Therapeutics Market, by Route Of Administration
13.1. Introduction
13.2. Intramuscular
13.3. Intravenous
13.4. Subcutaneous
14. Americas Next Generation Antibody Therapeutics Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Next Generation Antibody Therapeutics Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Next Generation Antibody Therapeutics Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie Inc.
17.3.2. Roche Holding AG
17.3.3. Merck & Co., Inc.
17.3.4. Johnson & Johnson
17.3.5. Bristol-Myers Squibb Company
17.3.6. Amgen Inc.
17.3.7. Novartis AG
17.3.8. Sanofi S.A.
17.3.9. Pfizer Inc.
17.3.10. AstraZeneca PLC
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. NEXT GENERATION ANTIBODY THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TARGET INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TARGET INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY EXPRESSION SYSTEM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY EXPRESSION SYSTEM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. NEXT GENERATION ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. NEXT GENERATION ANTIBODY THERAPEUTICS MARKET: RESEARCHAI
FIGURE 28. NEXT GENERATION ANTIBODY THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 29. NEXT GENERATION ANTIBODY THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 30. NEXT GENERATION ANTIBODY THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY CLEAVABLE LINKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY CLEAVABLE LINKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY NON CLEAVABLE LINKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY NON CLEAVABLE LINKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY FRAGMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY FRAGMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY BISPECIFIC T CELL ENGAGERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY BISPECIFIC T CELL ENGAGERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY DART, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY DART, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY DUAL VARIABLE DOMAIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY DUAL VARIABLE DOMAIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY RADIOLABELED ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY RADIOLABELED ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY IODINE 131, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY IODINE 131, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY YTTRIUM 90, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY YTTRIUM 90, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY RADIOLABELED ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY RADIOLABELED ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TARGET INDICATION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TARGET INDICATION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY HEART FAILURE, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ALZHEIMERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ALZHEIMERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PARKINSONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PARKINSONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY HYBRIDOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY HYBRIDOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PHAGE DISPLAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PHAGE DISPLAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY IMMUNE LIBRARY, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY IMMUNE LIBRARY, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY NAIVE LIBRARY, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY NAIVE LIBRARY, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY SYNTHETIC LIBRARY, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY SYNTHETIC LIBRARY, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PHAGE DISPLAY, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PHAGE DISPLAY, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY RIBOSOME DISPLAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY RIBOSOME DISPLAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY SINGLE B CELL TECHNOLOGIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY SINGLE B CELL TECHNOLOGIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY MICROENGRAVING, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY MICROENGRAVING, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY SINGLE B CELL TECHNOLOGIES, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY SINGLE B CELL TECHNOLOGIES, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TRANSGENIC ANIMALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TRANSGENIC ANIMALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAB MOUSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAB MOUSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY XENOMOUSE, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY XENOMOUSE, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TRANSGENIC ANIMALS, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TRANSGENIC ANIMALS, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY EXPRESSION SYSTEM, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY MAMMALIAN CELLS, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY MAMMALIAN CELLS, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY CHO CELLS, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY CHO CELLS, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY NS0 CELLS, BY REGION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY NS0 CELLS, BY REGION, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY SP2/0 CELLS, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY SP2/0 CELLS, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY MAMMALIAN CELLS, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY MAMMALIAN CELLS, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY MICROBIAL SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY MICROBIAL SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ESCHERICHIA COLI, BY REGION, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ESCHERICHIA COLI, BY REGION, 2025-2030 (USD MILLION)
TABLE 137. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY MICROBIAL SYSTEMS, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY MICROBIAL SYSTEMS, 2025-2030 (USD MILLION)
TABLE 139. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PLANT SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PLANT SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 141. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY NICOTIANA BENTHAMIANA, BY REGION, 2018-2024 (USD MILLION)
TABLE 142. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY NICOTIANA BENTHAMIANA, BY REGION, 2025-2030 (USD MILLION)
TABLE 143. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PLANT SYSTEMS, 2018-2024 (USD MILLION)
TABLE 144. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PLANT SYSTEMS, 2025-2030 (USD MILLION)
TABLE 145. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY YEAST SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 146. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY YEAST SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 147. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PICHIA PASTORIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 148. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PICHIA PASTORIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 149. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY SACCHAROMYCES CEREVISIAE, BY REGION, 2018-2024 (USD MILLION)
TABLE 150. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY SACCHAROMYCES CEREVISIAE, BY REGION, 2025-2030 (USD MILLION)
TABLE 151. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY YEAST SYSTEMS, 2018-2024 (USD MILLION)
TABLE 152. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY YEAST SYSTEMS, 2025-2030 (USD MILLION)
TABLE 153. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 154. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 155. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 156. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 157. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
TABLE 158. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PHASE I, BY REGION, 2025-2030 (USD MILLION)
TABLE 159. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
TABLE 160. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PHASE II, BY REGION, 2025-2030 (USD MILLION)
TABLE 161. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
TABLE 162. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PHASE III, BY REGION, 2025-2030 (USD MILLION)
TABLE 163. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
TABLE 164. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY CLINICAL TRIALS, 2025-2030 (USD MILLION)
TABLE 165. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 166. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY COMMERCIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 167. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 168. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PRECLINICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 169. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
TABLE 170. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY DISCOVERY, BY REGION, 2025-2030 (USD MILLION)
TABLE 171. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY NON CLINICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 172. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY NON CLINICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 173. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PRECLINICAL, 2018-2024 (USD MILLION)
TABLE 174. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PRECLINICAL, 2025-2030 (USD MILLION)
TABLE 175. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 176. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 177. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 178. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 179. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 180. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 181. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 182. GLOBAL NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 183. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY CLASS, 2018-2024 (USD MILLION)
TABLE 184. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY CLASS, 2025-2030 (USD MILLION)
TABLE 185. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
TABLE 186. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2030 (USD MILLION)
TABLE 187. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 188. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 189. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY RADIOLABELED ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 190. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY RADIOLABELED ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 191. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TARGET INDICATION, 2018-2024 (USD MILLION)
TABLE 192. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TARGET INDICATION, 2025-2030 (USD MILLION)
TABLE 193. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
TABLE 194. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2030 (USD MILLION)
TABLE 195. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
TABLE 196. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2030 (USD MILLION)
TABLE 197. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 198. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 199. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 200. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 201. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 202. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 203. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 204. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 205. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PHAGE DISPLAY, 2018-2024 (USD MILLION)
TABLE 206. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PHAGE DISPLAY, 2025-2030 (USD MILLION)
TABLE 207. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY SINGLE B CELL TECHNOLOGIES, 2018-2024 (USD MILLION)
TABLE 208. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY SINGLE B CELL TECHNOLOGIES, 2025-2030 (USD MILLION)
TABLE 209. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TRANSGENIC ANIMALS, 2018-2024 (USD MILLION)
TABLE 210. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TRANSGENIC ANIMALS, 2025-2030 (USD MILLION)
TABLE 211. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2024 (USD MILLION)
TABLE 212. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY EXPRESSION SYSTEM, 2025-2030 (USD MILLION)
TABLE 213. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY MAMMALIAN CELLS, 2018-2024 (USD MILLION)
TABLE 214. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY MAMMALIAN CELLS, 2025-2030 (USD MILLION)
TABLE 215. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY MICROBIAL SYSTEMS, 2018-2024 (USD MILLION)
TABLE 216. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY MICROBIAL SYSTEMS, 2025-2030 (USD MILLION)
TABLE 217. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PLANT SYSTEMS, 2018-2024 (USD MILLION)
TABLE 218. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PLANT SYSTEMS, 2025-2030 (USD MILLION)
TABLE 219. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY YEAST SYSTEMS, 2018-2024 (USD MILLION)
TABLE 220. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY YEAST SYSTEMS, 2025-2030 (USD MILLION)
TABLE 221. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 222. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 223. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
TABLE 224. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY CLINICAL TRIALS, 2025-2030 (USD MILLION)
TABLE 225. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PRECLINICAL, 2018-2024 (USD MILLION)
TABLE 226. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PRECLINICAL, 2025-2030 (USD MILLION)
TABLE 227. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 228. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 229. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 230. AMERICAS NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 231. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY CLASS, 2018-2024 (USD MILLION)
TABLE 232. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY CLASS, 2025-2030 (USD MILLION)
TABLE 233. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
TABLE 234. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2030 (USD MILLION)
TABLE 235. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 236. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY BISPECIFIC ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 237. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY RADIOLABELED ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 238. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY RADIOLABELED ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 239. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TARGET INDICATION, 2018-2024 (USD MILLION)
TABLE 240. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TARGET INDICATION, 2025-2030 (USD MILLION)
TABLE 241. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
TABLE 242. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2030 (USD MILLION)
TABLE 243. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2024 (USD MILLION)
TABLE 244. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2025-2030 (USD MILLION)
TABLE 245. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 246. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 247. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 248. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 249. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 250. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 251. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
TABLE 252. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2030 (USD MILLION)
TABLE 253. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PHAGE DISPLAY, 2018-2024 (USD MILLION)
TABLE 254. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PHAGE DISPLAY, 2025-2030 (USD MILLION)
TABLE 255. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY SINGLE B CELL TECHNOLOGIES, 2018-2024 (USD MILLION)
TABLE 256. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY SINGLE B CELL TECHNOLOGIES, 2025-2030 (USD MILLION)
TABLE 257. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TRANSGENIC ANIMALS, 2018-2024 (USD MILLION)
TABLE 258. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TRANSGENIC ANIMALS, 2025-2030 (USD MILLION)
TABLE 259. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2024 (USD MILLION)
TABLE 260. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY EXPRESSION SYSTEM, 2025-2030 (USD MILLION)
TABLE 261. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY MAMMALIAN CELLS, 2018-2024 (USD MILLION)
TABLE 262. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY MAMMALIAN CELLS, 2025-2030 (USD MILLION)
TABLE 263. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY MICROBIAL SYSTEMS, 2018-2024 (USD MILLION)
TABLE 264. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY MICROBIAL SYSTEMS, 2025-2030 (USD MILLION)
TABLE 265. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PLANT SYSTEMS, 2018-2024 (USD MILLION)
TABLE 266. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PLANT SYSTEMS, 2025-2030 (USD MILLION)
TABLE 267. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY YEAST SYSTEMS, 2018-2024 (USD MILLION)
TABLE 268. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY YEAST SYSTEMS, 2025-2030 (USD MILLION)
TABLE 269. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
TABLE 270. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
TABLE 271. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY CLINICAL TRIALS, 2018-2024 (USD MILLION)
TABLE 272. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY CLINICAL TRIALS, 2025-2030 (USD MILLION)
TABLE 273. UNITED STATES NEXT GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY PRECLINICAL, 2018-2024 (USD MILLION)
TABLE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Next Generation Antibody Therapeutics market report include:
  • AbbVie Inc.
  • Roche Holding AG
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • Novartis AG
  • Sanofi S.A.
  • Pfizer Inc.
  • AstraZeneca PLC

Related Topics

Related Reports

Cancer Monoclonal Antibodies Market - Global Forecast 2025-2030 - Product Image

Cancer Monoclonal Antibodies Market - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Monoclonal Antibody Therapeutics Market - Global Forecast 2025-2030 - Product Image

Monoclonal Antibody Therapeutics Market - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Antibody Discovery - Global Strategic Business Report - Product Image

Antibody Discovery - Global Strategic Business Report

  • Report
  • 224 Pages
  • Global
From
Next-Generation Antibody Therapeutics Market Report 2025 - Product Image

Next-Generation Antibody Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Antibody Discovery - Market Insights, Competitive Landscape, and Market Forecast - 2032 - Product Image

Antibody Discovery - Market Insights, Competitive Landscape, and Market Forecast - 2032

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.